Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | LTK | P29376 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.38 |
| ▸ | MERTK | Q12866 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18792011 | 1.00 | TRPV4 (0.44) | TRPV4ALKEGFRMAP3K7IRAK4 | |
| SCHEMBL18792012 | 1.00 | TRPV4 (0.44) | TRPV4ALKEGFRMAP3K7IRAK4 | |
| SCHEMBL18792015 | 0.91 | TRPV4 (0.47) | TRPV4ALKCYP11B2INSRLCK | |
| SCHEMBL20111282 | 0.91 | TRPV4 (0.47) | TRPV4ALKCYP11B2INSRLCK | |
| SCHEMBL18791668 | 0.91 | TRPV4 (0.47) | TRPV4ALKCYP11B2INSRLCK | |
| SCHEMBL17582910 | 0.91 | TRPV4 (0.47) | TRPV4ALKEGFRCYP11B2 | |
| SCHEMBL17582802 | 0.91 | TRPV4 (0.47) | TRPV4ALKEGFRCYP11B2 | |
| SCHEMBL30659132 | 0.91 | TRPV4 (0.47) | TRPV4ALKEGFRCYP11B2 | |
| SCHEMBL30659083 | 0.91 | TRPV4 (0.47) | TRPV4ALKEGFRCYP11B2 | |
| SCHEMBL30659146 | 0.91 | TRPV4 (0.47) | TRPV4ALKEGFRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2020-02-27 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| WO-2018081825-A1 | BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | TRPV4 97/4885ALK 2337/4885EGFR 4338/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | TRPV4 97/4885ALK 2337/4885EGFR 4338/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | TRPV4 97/4885ALK 2337/4885EGFR 4338/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | TRPV4 97/4885ALK 2337/4885EGFR 4338/4885 |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | TRPV4 104/4885ALK 3025/4885EGFR 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.